



Adam Telner MD, FRCP(C), FACP

* Adam Telner provides medical services through Dr. Adam Telner Medicine Professional Corporation

Bayview #107 & 125-1929 Bayview Avenue, Toronto, Ontario M4G 3E8 Canada Tel (416) 645-2929

CURRICULUM VITAE

Education, Certification & Licenses

Jan 2015	Advanced Cardiac Life Support (ACLS)	ACLS Certification Institute
1968	Honours Bachelor of Science (Genetics)	McGill University, Montreal, QC
1972	M.D.C.M	McGill University, Montreal, QC
1973	Masters of Science (Experimental Medicine)	McGill University, Montreal, QC
1978	F.R.C.P.(C) - Internal Medicine	
1978	American Board of Internal Medicine - Medicine	
1983	American Board of Internal Medicine - Endocrinology & Metabolism	
1985	F.A.C.P	
1985	Certification - Endocrinology & Metabolism (Canada)	

Professional Activities

2010-present	Associate, Endocrinologist	LMC Diabetes & Endocrinology
1979-2010	Department of Medical Staff	Queensway Carleton Hospital, Ottawa
1993-2000;2004-10	Consulting Staff	Division of Endocrinology and Metabolism, Ottawa Hospital
Apr 2002-Apr 2003	Acting Chief	Department of Geriatrics, Queensway Carleton Hospital
1993-1997	Clinical Tutor Endocrine Block	University of Ottawa
1993-1999	Chief, Department of Medicine	Queensway Carleton Hospital
July-Dec 2000	Endocrinology Consultant	Department of Medicine, Trillium Hospital, Mississauga

Postgraduate Education

1972-1973	Straight Internship in Medicine	Jewish General Hospital, Montreal, QC
1973-1974	Assistant Resident in Medicine	Jewish General Hospital, Montreal, QC
1974-1976	Fellow in Endocrinology & Metabolism	University of Michigan, Ann Arbor, MI (Supervisor: Dr. S. Fajans)
1976-1977	Resident in Endocrinology	Sunnybrook Medical Center, Toronto, ON (Supervisor: Dr. R. Sheppard)
1978-1979	Resident in Medicine	Sunnybrook Medical Center, Toronto, ON

Publications*

"Prevalence of Obstructive Sleep Apnea in Patients with Metabolic Syndrome", by **A Telner**, A Gervais International Diabetes Federation conference (for Oct 2009)

"Outcomes of a Multidisciplinary Approach to the Management of the Metabolic Syndrome", by **A Telner**, A Gervais, S Amos; Can Pharm J Jan 2008

Achievements, Associations & Specialties

Associations	Member, Ontario Medical Association
	Member, Canadian Society of Endocrinology and Metabolism
	Member, Canadian Diabetes Association, Clinical and Scientific Section
Awards	Commitment to Care & Service Award 2007 Physician & Pharmacist Team (Adam Telner & Alan Gervais)

Clinical Trials & Research Activities

2011-2016	1245.20 (Boehringer Ingelheim), TAK-875-304 (Takeda), TAK-875_306 (Takeda), REWIND (Eli Lilly), EFC11628 (Sanofi-aventis), EFC12261 (Sanofi-aventis), EFJE (Eli Lilly), M11-352 (AbbVie), 1245.48 (Boehringer Ingelheim), EFC12347 (Sanofi-aventis), EFC12456 (Sanofi-aventis), CV201-008 (Bristol-Myers Squibb), DECLARE 58 (AstraZeneca), RGN11110 (Regeneron), RGN1118 (Regeneron), GSN000200 (Genkyotex), APD356-G000-401 (Eisai), B1481022 (Pfizer), B1481038 (Pfizer), NN9211-3919 (Novo Nordisk), MK8835-002 (Merck), 034HVOL14005 (Retrophin), EFC12404/405 (Sanofi-aventis), CREDENCE (Janssen Research), B1481045 (Pfizer), J&J 2004 (Janssen Research), EFC13799 (Sanofi-aventis), STRENGTH (AstraZeneca), HARMONY 10 (GSK), LX4211.309 (Lexicon), PERL (Joslin Diabetes), LX4211.312 (Lexicon), DERIVE (AstraZeneca), NN9828-4150 (Novo Nordisk), DIAMOND (Dexcom), B4801010 (Pfizer), REMIT (PHRI), etc.
2010	28431754-DIA-3015 (J&J), DEFEND-1 (Tolerx), DEFEND-2 (Tolerx), Stability (GSK), EFC10781 (Sanofi-aventis), EFC6014 (Sanofi-aventis), EFC6016 (Sanofi-aventis), TIDE (GSK), 1245.20 (BI), SIBA 3643 (Novo Nordisk), MB102-029 (BMS), GBDN (Eli Lilly)

20 years of research experience, 10 clinical trials

* 16 publication in total. Detailed list available upon request.